CarePoint is introducing a multi-cancer early detection test to Hudson County patients thanks to a new partnership with GRAIL, LLC.
“As we strive to provide unparalleled care to the people of Hudson County, we’re proud to introduce cutting-edge multi-cancer early detection at our hospital,” CarePoint Health CMO Dr. John Rimmer said in a statement.
“CarePoint’s mission to embrace innovation is not just about treating illness, but about empowering prevention and saving lives as soon as it is possible. We are proud to partner with GRAIL to provide this innovative testing service to the Hudson County community.”
CarePoint patients who meet the eligibility criteria will now have access to GRAIL’s Galleri® multi-cancer early detection (MCED) test.
To be eligible for the screenings, patients must be established patients of one of CarePoint Health’s primary/specialty care practices, be at an elevated risk of cancer (such as individuals aged 50 or older), not be currently pregnant, and not be undergoing active cancer treatment or have completed cancer treatment at least five years ago (excluding basal or squamous cell carcinoma of the skin).
“We have an opportunity to shift the cancer screening paradigm with multi-cancer early detection tests to screen for a ‘fingerprint’ of the deadliest cancers before they become symptomatic, including those without recommended screening tests today,” added GRAIL CMO Dr. Jeffrey Venstrom.
“By offering the Galleri test to the patients of Hudson County, CarePoint Health is providing patients with the best chance to screen for, and ultimately diagnose many types of cancer early. We are pleased to share in their commitment to elevated patient care. The Galleri test, available by prescription only, is the first-of-its-kind clinically validated MCED test capable of detecting a shared cancer signal across more than 50 types of cancers using a simple blood draw.”
Following a positive Galleri test result, CarePoint will use this groundbreaking technology to support patients and providers throughout the diagnostic journey.
Plans to enhance patient experience and outcomes include standardizing patient and provider education, developing evidence-based diagnostic pathways, and facilitating timely evaluations.
“As far as modern medicine goes, this is our best shot at increasing our chances of beating cancer early and we are so proud to be able to provide this service to our patients,” noted CarePoint Chief of Staff and Vice President of Marketing and Patient Strategy Justin Drew.
“Here at CarePoint our patients’ health always comes first and this is just one of the ways in which we have aligned with our mission to provide high quality, innovative and compassionate care.”
According to the American Cancer Society, over 600,000 people die from cancer each year in the U.S., primarily due to late-stage diagnoses.
While recommended screening tests save lives, they only cover five cancer types in the country and approximately 70 percent of cancer deaths have no recommended early detection screening.
